Five Prime Therapeutics Культура компании

Dr. Lewis T. Williams, also known as Rusty, M.D, Ph.D, founded Five Prime Therapeutics, Inc. in December 2001 and has been its Executive Chairman since January 2018. Dr. Williams served as the President and CEO of Five Prime Therapeutics, Inc. from August 2011 to December 2017. Dr. Williams previously served as the Chairman of Five Prime Therapeutics, Inc. from January 2012 to January 2018. He served as the Chief Scientific Officer at Chiron Corporation since 1998 and also served as its President. He joined Chiron Corporation in August 1994 as Senior Vice President and President at Chiron Technologies (now called Chiron Research and Development). Prior to joining Five Prime, Dr. Williams spent seven years at Chiron Corporation, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., Dr. Williams was a Howard Hughes Medical Institute investigator at the University of California, San Francisco. Earlier in his career he was on the faculty of Harvard Medical School. He was a Co-Founder of COR Therapeutics Inc. He founded Fiveprime Therapeutics Inc., in 2002 and served as its Executive Chairman from July 2003 to January 2012. He serves as a Director at Fiveprime Therapeutics Inc., Comedicus Inc. and Berklee College of Music. He has been a Director of Juvaris BioTherapeutics Inc. since 2007. He served as a Director of Chiron Corporation from May 1999 to 2001. He serves as a Member of Scientific Advisory Board of Fiveprime Therapeutics Inc. He served as a Member of Scientific Advisory Board of Veracyte, Inc. He has been a Director at Protagonist Therapeutics, Inc. since June 08, 2017. He served as a Director of Beckman Coulter Inc. from October 23, 2009 to June 20, 2011. He served as a Director of COR Therapeutics Inc. from 1988 to August 1994. From 1992 to 1994, Dr. Williams served on the Scientific Advisory Board of Geron Corporation and Fiveprime Therapeutics, Inc. From 1988 to August 1994, he was a Professor of Medicine at the University of California, San Francisco. He served as Director of the University's Cardiovascular Research Institution and Daiichi Research Center. Prior to joining UCSF, he was on the faculty of Harvard Medical School. He served as Executive Chairman of Five Prime Therapeutics, Inc. from July 2003 to January 2012. He has been a Director of Five Prime Therapeutics, Inc. since January 2002. He served as a Trustee of Duke University until May 2009. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts & Sciences. Dr. Williams received his M.D. and Ph.D. degrees from Duke University. He holds B.S. from Rice University. He trained in Internal Medicine and Cardiology at the Massachusetts General Hospital.

Mr. Aron Marc Knickerbocker has been the Chief Operating Officer of Five Prime Therapeutics, Inc. since September 8, 2016. Mr. Knickerbocker served as the Chief Business Officer of Five Prime Therapeutics, Inc. since April 2012 and as its Executive Vice President since August 17, 2015. Mr. Knickerbocker served as Senior Vice President of Five Prime Therapeutics, Inc. from April 2012 to August 17, 2015 and as its Vice President of Business Development from October 2009 to April 2012. He has substantial experience in business development licensing and corporate development. Mr. Knickerbocker leads FivePrime's business development and licensing activities to accelerate advancement of its drug pipeline and continue to mine its robust discovery platform for innovative biologics. Mr. Knickerbocker joined FivePrime from Genentech, Inc. where he most recently served as senior director, business development, leading Genentech's oncology business development team and responsible for evaluating and negotiating strategic alliances. He has worked previously with Alza Corporation, where he managed licensing transactions as their director of commercial development and held sales, market research, marketing and corporate development positions at Amgen, Inc. He began his career in the biopharmaceutical industry in research as a scientist at Bristol-Myers Squibb. He has been a Director of Five Prime Therapeutics, Inc. since October 23, 2013. Mr. Knickerbocker received his B.A. degree in biology from Washington University in St. Louis and his M.B.A. degree from the University of Michigan.

Dr. Kevin P. Baker, Ph.D., has been Senior Vice President of Development Sciences at Five Prime Therapeutics, Inc. since February 1, 2016. Dr. Baker served as Senior Vice President of Preclinical Development at Audentes Therapeutics, Inc. since September 2015. Dr. Baker served as Vice President of Preclinical Development at Five Prime Therapeutics, Inc. Prior to joining FivePrime in 2006, he served as an Associate Director of Protein Therapeutics at Human Genome Sciences, where he led preclinical development teams developing therapeutic antibody programs in autoimmune disease and research teams focused on receptor-ligand interactions in the immune system. He served as Vice President of Preclinical Development at Five Prime Therapeutics, Inc. since January 2006 until July 2015. He began his career in the biotechnology industry as a Scientist at Genentech Inc., where among other activities he led a research group involved in the identification and cloning of genes encoding secreted proteins. He has over 24 years of research experience, with 16 of that in the biotechnology industry. His education includes Postdoctoral Training in Molecular Cell Biology at the Biozentrum, University of Basel, Switzerland and a Ph D in Molecular Biology from the University of Dundee, Scotland. Dr. Baker received a Bachelor of Science in Biochemistry and Physiology from the University of Salford, England.

Mr. Marc L. Belsky has been the Chief Financial Officer and Senior Vice President at Five Prime Therapeutics, Inc. since December 2013. Mr. Belsky served as Vice President of Finance at Five Prime Therapeutics, Inc. since October 2009. At Five Prime Therapeutics, Inc., he leads its finance and accounting group. Mr. Belsky served as Vice President of Finance and Chief Accounting Officer of Cell Genesys Inc. since December 1, 2006. Mr. Belsky has more than 20 years of executive and senior management experience in finance and accounting. Mr. Belsky served as Vice President of Global Visa Commerce of Visa International Service Association from September 2005 to November 2006. Prior to Visa, he held senior management positions in other companies including Chief Financial Officer of Active Aero Group from March 2003 to September 2005, as well as Senior finance and banking positions of Michigan National Corp. from 1986 to 2001. Mr. Belsky started his career as an Auditor of Coopers & Lybrand. He served as the Chief Financial Officer of Datawave Systems, Inc. from July 2001 to March 2003. Mr. Belsky served as First Vice President of Planning and Analysis of Michigan National Corporation since 1990 and First Vice President of Michigan National Bank, a subsidiary of Michigan National Corp. since 1990, Vice President of Michigan National Bank since 1986, Treasurer of MNC Leasing Company, a subsidiary of Michigan National Corp. since 1990 and Treasurer of MNC Financial Services since 1990. Mr. Belsky served as Treasurer of Independence One Investment Services Corp., a subsidiary of Michigan National Corp. from 1989 to 1990 and Chief Financial Officer and Treasurer of Independence One Capital Management Corporation from 1989 to 1990. He served as Head of Strategy for National Australia Bank's Asia Pacific Cards Group. Mr. Belsky served as a Director at Datawave Systems, Inc. until March 2003. Mr. Belsky is a Certified Public Accountant, a Certified Treasury Professional and holds a Master of Business Administration from the University of Michigan and a B.S. in accounting from Wayne State University.

Mr. Francis W. Sarena has been Secretary at Five Prime Therapeutics, Inc. since December 2010 and has been its Chief Strategy Officer since September 2016. Mr. Sarena served as an Executive Vice President at Five Prime Therapeutics, Inc., since August 2015 until September 2016 and its General Counsel since December 2010 until September 15, 2016. He served as Vice President at Five Prime Therapeutics, Inc. from December 2010 to January 2013. Mr. Sarena served as a Senior Vice President of Five Prime Therapeutics, Inc. from January 2013 to August 2015. He served as Secretary, Vice President and General Counsel of Facet Biotech Corporation. He served as Chief Legal Officer of PDL BioPharma, Inc. since January 2008. He joined PDL BioPharma, Inc. in April 2006 and served as its Corporate Counsel and also its Assistant Secretary since June 2007. He served as Vice President, Secretary and General Counsel of Abbott Biotherapeutics Corp. (also known as PDL BioPharma, Inc.) since December 2008. From September 2000 to April 2006, Mr. Sarena served as Corporate Associate at Bingham McCutchen LLP primarily focused on representing clients in merger and acquisition transactions, corporate and securities law matters and equity financing transactions. He was Legal Professional at McCutchen, Doyle, Brown & Enersen, LLP. He served as Executive Director of PDL BioPharma, Inc. since January 2008. Mr. Sarena received his J.D. from University of California, Berkeley, Boalt Hall School of Law and his B.S. in Finance from San Francisco State University.

Dr. Bryan Irving, Ph.D., has been Senior Vice President of Research at Five Prime Therapeutics, Inc. since September 01, 2017. Dr. Irving served as Vice President of Cancer Immunology at CytomX Therapeutics, Inc. since August 3, 2015. Dr. Irving served as Senior Director of Cancer Immunology at CytomX Therapeutics, Inc. Dr. Irving was with CytomX Therapeutics, Inc from December 2013 to August 2017. From September 2001 to November 2013, Dr. Irving served as a scientist at Genentech, Inc., where his research focused in both areas of inflammation and immuno-oncology. Dr. Irving held positions in academia, where he conducted influential research into the single-chain chimeric antigen receptor (CAR) technology is being used in patients' T cells to treat hematologic malignancies. Dr. Irving served as a Postdoctoral Fellow at both Harvard University and the University of California, San Francisco. Dr. Irving received a Ph.D. in Immunology from the University of California, San Francisco and a B.A. in Physiology from the University of California, Berkeley.

Dr. Helen Louise Collins, M.D., has been Senior Vice President and Chief Medical Officer of Five Prime Therapeutics, Inc. since March 18, 2017. Dr. Collins has more than 20 years of oncology expertise, as well as clinical development and medical affairs experience. She joined Five Prime in June 2016 as Vice President of Clinical Development and has been instrumental in leading the Five Prime's clinical development programs. From June 2013 to June 2016, she held positions of increasing responsibility at Gilead Sciences, Inc. including Program and Clinical Lead for Gileads GS-5829 (BET inhibitor) and GS-4059 (BTK inhibitor) programs. From November 2009 to May 2013, she held positions of increasing responsibility at Amgen Inc., including Global Lead of Oncology Biosimiliars. Prior to joining Amgen, she practiced as a Medical Oncologist and Hematologist for 12 years at Redwood Regional Medical Group (RRMG) and served as President of RRMG from 2006 to 2009. In 2005, she Co-Founded the non-profit North Bay Cancer Alliance (NBCA), whose mission is to increase local access to education and cancer care in counties in the northern San Francisco Bay Area. Dr. Collins is board certified in both Oncology and Internal Medicine. Dr. Collins completed her residency in internal medicine at Johns Hopkins Hospital and completed her fellowship at Stanford University School of Medicine, where, she concentrated in gastrointestinal cancer. Dr. Collins received an A.B. in Chemistry from Bryn Mawr College and an M.D. from Johns Hopkins University School of Medicine.

Bryan Irving serves as the Executive Vice President and Chief Scientific Officer of Five Prime Therapeutics, Inc.. Bryan started at Five Prime Therapeutics, Inc. in May of 2018. Bryan currently resides in the San Francisco Bay Area.

Nallakkan A serves as the Senior Vice President, Strategic Technology Operations of Five Prime Therapeutics, Inc.. Nallakkan started at Five Prime Therapeutics, Inc. in Feb of 2018. Nallakkan currently resides in the San Francisco Bay Area.

Tarak Mody serves as the Vice President Business Development & Alliance Management of Five Prime Therapeutics, Inc.. Tarak started at Five Prime Therapeutics, Inc. in Jul of 2016. Tarak currently resides in the San Francisco Bay Area.